Related Experiment Video
Updated: May 20, 2026

Growing Desmoplastic Three-Dimensional Pancreatic Cancer Spheroids from Co-Culture
Published on: September 27, 2024
Cell intrinsic role of COX-2 in pancreatic cancer development
Reginald Hill1, Yunfeng Li, Linh M Tran
1Corresponding Author: Hong Wu, Department of Molecular and Medical Pharmacology, CHS 33-131, 650 CE Young Drive South, Los Angeles, CA 90095, USA.
Abstract:
COX-2 is upregulated in pancreatic ductal adenocarcinomas (PDAC). However, how COX-2 promotes PDAC development is unclear. While previous studies have evaluated the efficacy of COX-2 inhibition via the use of nonsteroidal anti-inflammatory drugs (NSAID) or the COX-2 inhibitor celecoxib in PDAC models, none have addressed the cell intrinsic versus microenvironment roles of COX-2 in modulating PDAC initiation and progression. We tested the cell intrinsic role of COX-2 in PDAC progression using both loss-of-function and gain-of-function approaches. Cox-2 deletion in Pdx1+ pancreatic progenitor cells significantly delays the development of PDAC in mice with K-ras activation and Pten haploinsufficiency. Conversely, COX-2 overexpression promotes early onset and progression of PDAC in the K-ras mouse model. Loss of PTEN function is a critical factor in determining lethal PDAC onset and overall survival. Mechanistically, COX-2 overexpression increases p-AKT levels in the precursor lesions of Pdx1(+); K-ras(G12D)(/+); Pten(lox)(/+) mice in the absence of Pten LOH. In contrast, Cox-2 deletion in the same setting diminishes p-AKT levels and delays cancer progression. These data suggest an important cell intrinsic role for COX-2 in tumor initiation and progression through activation of the PI3K/AKT pathway. PDAC that is independent of intrinsic COX-2 expression eventually develops with decreased FKBP5 and increased GRP78 expression, two alternate pathways leading to AKT activation. Together, these results support a cell intrinsic role for COX-2 in PDAC development and suggest that while anti-COX-2 therapy may delay the development and progression of PDAC, mechanisms known to increase chemoresistance through AKT activation must also be overcome.
Insights
Cyclooxygenase-2 (COX-2) plays a cell-intrinsic role in pancreatic ductal adenocarcinoma (PDAC) development by activating the PI3K/AKT pathway. Inhibiting COX-2 may delay PDAC, but overcoming AKT-mediated chemoresistance is also crucial.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Pancreatic ductal adenocarcinoma (PDAC) shows upregulated Cyclooxygenase-2 (COX-2), but its specific role in tumor initiation and progression remains unclear.
- Previous research focused on COX-2 inhibition using NSAIDs or celecoxib, without distinguishing between cell-intrinsic and microenvironment effects.
- The interplay between COX-2, PTEN loss, and the PI3K/AKT pathway in PDAC pathogenesis requires further elucidation.
Purpose of the Study:
- To investigate the cell-intrinsic role of COX-2 in pancreatic cancer initiation and progression.
- To elucidate the molecular mechanisms by which COX-2 influences PDAC development, particularly concerning the PI3K/AKT pathway.
- To assess the potential of targeting COX-2 in PDAC treatment strategies.
Main Methods:
- Utilized loss-of-function (Cox-2 deletion) and gain-of-function (COX-2 overexpression) approaches in genetically engineered mouse models (GEMMs) of PDAC.
- Employed Pdx1-Cre, K-ras, and Pten conditional knockout mouse models to study PDAC development.
- Analyzed molecular changes including p-AKT, FKBP5, and GRP78 expression levels in precursor lesions and tumors.
Main Results:
- Cox-2 deletion in pancreatic progenitor cells significantly delayed PDAC development in mice with K-ras activation and Pten haploinsufficiency.
- COX-2 overexpression accelerated PDAC onset and progression in the K-ras mouse model.
- Mechanistically, COX-2 overexpression increased p-AKT levels, while Cox-2 deletion diminished them, indicating a role in PI3K/AKT pathway activation.
- Alternative pathways involving FKBP5 and GRP78 can lead to AKT activation, driving PDAC progression independent of intrinsic COX-2.
Conclusions:
- COX-2 exerts a significant cell-intrinsic role in PDAC initiation and progression, primarily through the activation of the PI3K/AKT pathway.
- Targeting COX-2 may offer a therapeutic strategy to delay PDAC development and progression.
- Overcoming compensatory AKT activation pathways is essential for enhancing the efficacy of anti-COX-2 therapies in PDAC treatment.
Related Concept Videos
The Intrinsic Apoptotic Pathway
Chronic Pancreatitis II: Pathophysiology
Acute Pancreatitis II: Pathophysiology
Inhibition of Cdk Activity
Cancer Cell Migration through Invadopodia
Induced Pluripotent Stem Cells
Somatic cells are...

